NCT03303144View on ClinicalTrials.gov

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

December 28, 2017

Study Completion Date

December 28, 2017

Conditions

End Stage Renal Disease

Interventions

DRUG

Triferic

ferric pyrophosphate citrate

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

All Listed Sponsors

lead

Rockwell Medical Technologies, Inc.

INDUSTRY

NCT03303144 - Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients | Biotech Hunter | Biotech Hunter